MILFORD, Mass., April 13, 2012 /PRNewswire/ -- PLC Systems Inc. (OTC: PLCSF), a company focused on innovative medical device technologies, today announced that its innovative RenalGuard System™ is being demonstrated at two major cardiology meetings: Jahrestagung der DGK, the 78th Annual Congress of the German Society of Cardiology, April 11-14, 2012 in Mannheim, Germany, and the 59th Annual Conference of the Israel Heart Society, April 16-17, 2012 in Tel-Aviv, Israel. Both ACIST Medical Systems, PLC's distributor in Germany, and A.M.I. Technologies, its distributor in Israel, are exhibiting RenalGuard in their booths at the events, demonstrating its ease of use along with scientific data supporting its efficacy to potential customers. More than 8,000 clinicians and professionals are expected to attend the two conferences.
Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "These conferences are premier cardiovascular events in Germany and Israel, two major new markets for RenalGuard®. RenalGuard is being displayed in both the ACIST and A.M.I. booths at these events, providing important exposure of our new technology to global knowledge leaders, and current and potential customers."
In March 2012, A.M.I. became the exclusive distributor of RenalGuard in Israel, and secured Ministry of Health approval to market and distribute RenalGuard in the country. In October 2011, ACIST became the exclusive distributor of PLC's RenalGuard in Germany and France, the two largest countries in the European Union.
About PLC SystemsPLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA. This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2011, a copy of which is on file with the SEC. PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc. Contact: Mary T. Conway508-520-2545 firstname.lastname@example.org SOURCE PLC Systems Inc.